

AMENDMENTS

In the claims:

Claims 1-50 (Cancelled).

51. (Currently Amended) A chimeric ~~or humanized~~ anti- $\alpha 5\beta 1$ integrin antibody comprising:
- a heavy chain variable region ~~comprising~~ consisting of the amino acid sequence ~~having at least 95% identity to~~ of SEQ ID NO: 1;
 - a light chain variable region ~~comprising~~ consisting of the amino acid sequence ~~having at least 95% identity to~~ of SEQ ID NO: 7; and
 - a constant region, wherein the source of the constant region is a human IgG.
52. (Currently Amended) The ~~chimeric or humanized~~ anti- $\alpha 5\beta 1$ integrin antibody of claim 51, wherein the source of the constant region is human IgG4 or IgG2M3.
53. (Currently Amended) A pharmaceutical composition comprising ~~The chimeric or humanized anti- $\alpha 5\beta 1$ integrin antibody of claim 52~~ 51, and a physiologically acceptable carrier, wherein the source of the constant region is human IgG4.
54. (Currently Amended) ~~The~~ A chimeric ~~or humanized~~ anti- $\alpha 5\beta 1$ integrin antibody of claim 52, wherein the comprising:
- _____ a heavy chain variable region consisting of the amino acid sequence comprises of SEQ ID NO: ~~4~~ 16, and
 - _____ the a light chain variable region consisting of the amino acid sequence comprises of SEQ ID NO: ~~7~~ 18.
55. (Currently Amended) ~~An~~ A pharmaceutical composition ~~comprising the anti- $\alpha 5\beta 1$ integrin antibody of claim 54, and a physiologically acceptable carrier~~ comprising: a heavy chain ~~comprising an amino acid sequence having at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 25, 28, and 31;~~ a light chain ~~comprising an amino acid sequence having at least 95% identity to a~~

~~sequence selected from the group consisting of SEQ ID NOs: 7, 26, and 32; and
wherein the antibody inhibits angiogenesis stimulated by VEGF.~~

56. (Currently Amended) ~~The~~ A chimeric anti- $\alpha 5\beta 1$ integrin antibody of ~~claim 55,~~
~~wherein the light and~~ comprising:
_____ a heavy chain variable region consisting of the amino acid polypeptide sequences
comprise amino acid sequences having at least 95% identity to of SEQ ID NOs: 26-20;
and
_____ a light chain variable region consisting of the amino acid sequence of SEQ ID
NO: 2522, respectively.

57. (Currently Amended) ~~The~~ A pharmaceutical composition comprising the anti- $\alpha 5\beta 1$
integrin antibody of claim 55 56, and a physiologically acceptable carrier wherein the
light and heavy chain polypeptide sequences comprise amino acid sequences having
at least 95% identity to SEQ ID NOs: 26 and 28, respectively.

58. (Currently Amended) ~~The~~ A chimeric anti- $\alpha 5\beta 1$ integrin antibody of ~~claim 55,~~
~~wherein the light and~~ comprising:
_____ a heavy chain polypeptide sequences comprise consisting of the amino acid
sequences having at least 95% identity to of SEQ ID NOs: 32-25; and
_____ a light chain consisting of the amino acid sequence of SEQ ID NO: 2631,
respectively.

59. (Currently Amended) A pharmaceutical composition comprising the chimeric or
humanized anti- $\alpha 5\beta 1$ integrin antibody of claim 58, and a physiologically acceptable
carrier comprising:
_____ a heavy chain comprising an amino acid sequence selected from the group
consisting of SEQ ID NOs: 25, 28, and 31; and
_____ a light chain comprising an amino acid sequence selected from the group
consisting of SEQ ID NOs: 26, and 32.

60. (Currently Amended) ~~The~~ A chimeric or humanized anti- $\alpha 5\beta 1$ integrin antibody
comprising: of claim 59, wherein the

~~_____ a heavy chain polypeptide consisting of the amino acid sequence comprises of~~
SEQ ID NO: 25-28; and
~~_____ the a light chain polypeptide consisting of the amino acid sequence comprises of~~
SEQ ID NO: 2626.

61. (Currently Amended) ~~The chimeric or humanized anti- α 5 β 1 integrin~~
A
pharmaceutical composition comprising the antibody of claim 5960, and a
physiologically acceptable carrier~~wherein the heavy chain polypeptide sequence~~
~~comprises SEQ ID NO: 28 and the light chain polypeptide sequence comprises SEQ~~
~~ID NO: 26.~~

62. (Currently Amended) ~~The chimeric or~~A humanized anti- α 5 β 1 integrin antibody of
claim 59, ~~wherein the~~comprising:
~~_____ a heavy chain polypeptide consisting of the amino acid sequence comprises SEQ~~
ID NO: 31; and
~~_____ the a light chain polypeptide consisting of the amino acid sequence comprises of~~
SEQ ID NO: 32.

63. (Currently Amended) A pharmaceutical composition comprising ~~an anti- α 5 β 1~~
~~integrin~~the antibody ~~according to any one of claims 51, 55, or 5962,~~ and a
physiologically acceptable carrier.

Claims 64-78 (Cancelled).